[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.201.14. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 10, 1965

Serum Hyperviscosity Syndrome

Author Affiliations

From the Immunology Branch and Metabolism Service, National Cancer Institute, US Public Health Service, Department of Health, Education and Welfare, Bethesda, Md.

JAMA. 1965;192(6):464-467. doi:10.1001/jama.1965.03080190030008
Abstract

The hyperviscosity syndrome commonly includes mucous membrane bleeding, retinopathy and loss of vision, and neurological disorders associated with elevated serum viscosity. These changes can be lethal. Hyperviscosity, however, can be relieved by adequate plasmapheresis, and recognition of the hyperviscosity syndrome is important for the institution of the proper therapy.

The association of elevated serum viscosity with marked hypergammaglobulinemia has been recognized for more than 30 years. Between 1932 and 1937 Reismann,1 Magnus-Levy,2 and Albers3 reported increased serum viscosity in several patients with multiple myeloma. In 1944 Waldenström described an elevated serum viscosity in patients with macroglobulinemia.4 These findings have been extended in recent years by the delineation of a group of clinical symptoms attributable to increased viscosity of the blood.5-10

The hyperviscosity syndrome is frequently seen in patients with macroglobulinemia, with or without demonstrable lymphoma, but only rarely with multiple myeloma. Manifestations of the hyperviscosity

×